Kevin Corbett | Chief Executive Officer

J. Kevin Stitt | Governor

OHCA 2022-12

August 15, 2022

## Re: Prior Authorization of Oncaspar® and Mvasi® – Effective September 15, 2022

Dear Provider,

As authorized by Oklahoma Administrative Code 317:30-5-77.2

(https://oklahoma.gov/ohca/policies-and-rules/xpolicy.html), effective September 15, 2022, the Oklahoma Health Care Authority (OHCA) will require a prior authorization (PA) for Oncaspar® (pegaspargase) and Mvasi® (bevacizumab-awwb). No prior authorization is required for Avastin® (bevacizumab) and Zirabev® (bevacizumab-bvzr). If a SoonerCare member is currently on therapy with Oncaspar® or Mvasi®, the medication will be approved for continuation of therapy.

Sometimes medical claims lag behind the treatment date which causes an inability for OHCA staff to verify current therapy. In order to avoid a disruption in therapy, it is recommended that a PA request be submitted for members who started on therapy after June 30, 2022. If the member has already received therapy, dates of previous doses must be listed on the PA form.

The specific PA requirements for Oncaspar® and for the bevacizumab products are located on the OHCA website at <a href="www.oklahoma.gov/ohca/pa">www.oklahoma.gov/ohca/pa</a> in the "Oncologic" therapeutic category. Drugspecific PA forms are required for Oncaspar® (PHARM-153) and Mvasi® (PHARM-166), which are located on the OHCA website at <a href="www.oklahoma.gov/ohca/rxforms">www.oklahoma.gov/ohca/rxforms</a>.

All medication PA requests are submitted to the Pharmacy Prior Authorization Unit at the fax number located at the bottom of the PA form. Do **not** submit the requests to the Medical Authorization Unit or online via the provider portal.

If you have questions, please contact the Pharmacy Prior Authorization Unit at (800) 522-0114, option  $^{4}$ 

Thank you for your continued service to our SoonerCare members.

Sincerely.

Traylor Rains State Medicaid Director







Admin: 405-522-7300 Helpline: 800-987-7767